JP6884774B2 - 生体液よりタンパク質ベースの毒素とカリウムを除去するための多機能性の血液適合性多孔性ポリマービーズ吸着剤 - Google Patents
生体液よりタンパク質ベースの毒素とカリウムを除去するための多機能性の血液適合性多孔性ポリマービーズ吸着剤 Download PDFInfo
- Publication number
- JP6884774B2 JP6884774B2 JP2018520396A JP2018520396A JP6884774B2 JP 6884774 B2 JP6884774 B2 JP 6884774B2 JP 2018520396 A JP2018520396 A JP 2018520396A JP 2018520396 A JP2018520396 A JP 2018520396A JP 6884774 B2 JP6884774 B2 JP 6884774B2
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- polymer system
- biocompatible
- biocompatible polymer
- kda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920000642 polymer Polymers 0.000 title claims description 192
- 239000011324 bead Substances 0.000 title claims description 67
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 title claims description 40
- 239000011591 potassium Substances 0.000 title claims description 39
- 229910052700 potassium Inorganic materials 0.000 title claims description 39
- 239000003053 toxin Substances 0.000 title claims description 34
- 231100000765 toxin Toxicity 0.000 title claims description 34
- 108700012359 toxins Proteins 0.000 title claims description 34
- 102000004169 proteins and genes Human genes 0.000 title claims description 27
- 108090000623 proteins and genes Proteins 0.000 title claims description 27
- 239000003463 adsorbent Substances 0.000 title description 25
- 239000013060 biological fluid Substances 0.000 title description 2
- 210000004369 blood Anatomy 0.000 claims description 53
- 239000008280 blood Substances 0.000 claims description 53
- 229920000249 biocompatible polymer Polymers 0.000 claims description 51
- 239000000178 monomer Substances 0.000 claims description 46
- 239000011148 porous material Substances 0.000 claims description 43
- 108010054147 Hemoglobins Proteins 0.000 claims description 23
- 102000001554 Hemoglobins Human genes 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 230000002757 inflammatory effect Effects 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 22
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 21
- -1 monolithic columns Substances 0.000 claims description 19
- 102000004127 Cytokines Human genes 0.000 claims description 18
- 108090000695 Cytokines Proteins 0.000 claims description 18
- 150000002500 ions Chemical class 0.000 claims description 18
- 239000003431 cross linking reagent Substances 0.000 claims description 17
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 17
- 210000003743 erythrocyte Anatomy 0.000 claims description 16
- 229920002554 vinyl polymer Polymers 0.000 claims description 16
- 150000002632 lipids Chemical class 0.000 claims description 14
- 239000000017 hydrogel Substances 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 238000000576 coating method Methods 0.000 claims description 12
- 108010062374 Myoglobin Proteins 0.000 claims description 11
- 102000036675 Myoglobin Human genes 0.000 claims description 11
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 11
- 230000010412 perfusion Effects 0.000 claims description 11
- 150000003254 radicals Chemical class 0.000 claims description 11
- 125000000524 functional group Chemical group 0.000 claims description 10
- 238000006116 polymerization reaction Methods 0.000 claims description 10
- 239000000427 antigen Substances 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 230000000975 bioactive effect Effects 0.000 claims description 8
- 108010088751 Albumins Proteins 0.000 claims description 7
- 102000009027 Albumins Human genes 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims description 6
- 125000002130 sulfonic acid ester group Chemical group 0.000 claims description 6
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims description 6
- 238000010557 suspension polymerization reaction Methods 0.000 claims description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 5
- 238000007334 copolymerization reaction Methods 0.000 claims description 5
- 229960002897 heparin Drugs 0.000 claims description 5
- 229920000669 heparin Polymers 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 231100000699 Bacterial toxin Toxicity 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 4
- 108090000288 Glycoproteins Proteins 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 102000013967 Monokines Human genes 0.000 claims description 4
- 108010050619 Monokines Proteins 0.000 claims description 4
- 102000035195 Peptidases Human genes 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 102000029797 Prion Human genes 0.000 claims description 4
- 108091000054 Prion Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 239000000688 bacterial toxin Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940047124 interferons Drugs 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 231100000617 superantigen Toxicity 0.000 claims description 4
- 230000002227 vasoactive effect Effects 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 239000002158 endotoxin Substances 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 238000012662 bulk polymerization Methods 0.000 claims description 2
- 238000007720 emulsion polymerization reaction Methods 0.000 claims description 2
- 238000012673 precipitation polymerization Methods 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 description 35
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 33
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 24
- 239000012190 activator Substances 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 239000011734 sodium Substances 0.000 description 21
- 210000002381 plasma Anatomy 0.000 description 20
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 16
- 229920001429 chelating resin Polymers 0.000 description 16
- 239000011521 glass Substances 0.000 description 16
- TXBCBTDQIULDIA-UHFFFAOYSA-N 2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)CO TXBCBTDQIULDIA-UHFFFAOYSA-N 0.000 description 15
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 238000001914 filtration Methods 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000001179 sorption measurement Methods 0.000 description 12
- 230000006378 damage Effects 0.000 description 11
- 239000002270 dispersing agent Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 238000006277 sulfonation reaction Methods 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000001951 hemoperfusion Effects 0.000 description 9
- 208000002682 Hyperkalemia Diseases 0.000 description 8
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 208000007536 Thrombosis Diseases 0.000 description 7
- 208000007587 Transfusion-Related Acute Lung Injury Diseases 0.000 description 7
- HZWXJJCSDBQVLF-UHFFFAOYSA-N acetoxysulfonic acid Chemical compound CC(=O)OS(O)(=O)=O HZWXJJCSDBQVLF-UHFFFAOYSA-N 0.000 description 7
- 230000001186 cumulative effect Effects 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 7
- 229920002451 polyvinyl alcohol Polymers 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000004342 Benzoyl peroxide Substances 0.000 description 6
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 6
- 239000004793 Polystyrene Substances 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 235000019400 benzoyl peroxide Nutrition 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000003999 initiator Substances 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 6
- 229920002223 polystyrene Polymers 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000004580 weight loss Effects 0.000 description 6
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 5
- 229920001311 Poly(hydroxyethyl acrylate) Polymers 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 5
- 239000004809 Teflon Substances 0.000 description 5
- 229920006362 Teflon® Polymers 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000010836 blood and blood product Substances 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 230000015271 coagulation Effects 0.000 description 5
- 238000007306 functionalization reaction Methods 0.000 description 5
- 239000003456 ion exchange resin Substances 0.000 description 5
- 229920003303 ion-exchange polymer Polymers 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000003361 porogen Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 4
- SJIXRGNQPBQWMK-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-methylprop-2-enoate Chemical compound CCN(CC)CCOC(=O)C(C)=C SJIXRGNQPBQWMK-UHFFFAOYSA-N 0.000 description 4
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 4
- GNSFRPWPOGYVLO-UHFFFAOYSA-N 3-hydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCO GNSFRPWPOGYVLO-UHFFFAOYSA-N 0.000 description 4
- QZPSOSOOLFHYRR-UHFFFAOYSA-N 3-hydroxypropyl prop-2-enoate Chemical compound OCCCOC(=O)C=C QZPSOSOOLFHYRR-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical class OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 4
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 4
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 4
- 102000054727 Serum Amyloid A Human genes 0.000 description 4
- 108700028909 Serum Amyloid A Proteins 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- MPMBRWOOISTHJV-UHFFFAOYSA-N but-1-enylbenzene Chemical compound CCC=CC1=CC=CC=C1 MPMBRWOOISTHJV-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000035602 clotting Effects 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 229940027941 immunoglobulin g Drugs 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229920000352 poly(styrene-co-divinylbenzene) Polymers 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 229910001414 potassium ion Inorganic materials 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 230000037452 priming Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000012925 reference material Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- NWRZGFYWENINNX-UHFFFAOYSA-N 1,1,2-tris(ethenyl)cyclohexane Chemical compound C=CC1CCCCC1(C=C)C=C NWRZGFYWENINNX-UHFFFAOYSA-N 0.000 description 3
- WVAFEFUPWRPQSY-UHFFFAOYSA-N 1,2,3-tris(ethenyl)benzene Chemical compound C=CC1=CC=CC(C=C)=C1C=C WVAFEFUPWRPQSY-UHFFFAOYSA-N 0.000 description 3
- MYWOJODOMFBVCB-UHFFFAOYSA-N 1,2,6-trimethylphenanthrene Chemical compound CC1=CC=C2C3=CC(C)=CC=C3C=CC2=C1C MYWOJODOMFBVCB-UHFFFAOYSA-N 0.000 description 3
- QLLUAUADIMPKIH-UHFFFAOYSA-N 1,2-bis(ethenyl)naphthalene Chemical compound C1=CC=CC2=C(C=C)C(C=C)=CC=C21 QLLUAUADIMPKIH-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 208000010718 Multiple Organ Failure Diseases 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 3
- DAKWPKUUDNSNPN-UHFFFAOYSA-N Trimethylolpropane triacrylate Chemical compound C=CC(=O)OCC(CC)(COC(=O)C=C)COC(=O)C=C DAKWPKUUDNSNPN-UHFFFAOYSA-N 0.000 description 3
- OKKRPWIIYQTPQF-UHFFFAOYSA-N Trimethylolpropane trimethacrylate Chemical compound CC(=C)C(=O)OCC(CC)(COC(=O)C(C)=C)COC(=O)C(C)=C OKKRPWIIYQTPQF-UHFFFAOYSA-N 0.000 description 3
- GQPVFBDWIUVLHG-UHFFFAOYSA-N [2,2-bis(hydroxymethyl)-3-(2-methylprop-2-enoyloxy)propyl] 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(CO)(CO)COC(=O)C(C)=C GQPVFBDWIUVLHG-UHFFFAOYSA-N 0.000 description 3
- CQHKDHVZYZUZMJ-UHFFFAOYSA-N [2,2-bis(hydroxymethyl)-3-prop-2-enoyloxypropyl] prop-2-enoate Chemical compound C=CC(=O)OCC(CO)(CO)COC(=O)C=C CQHKDHVZYZUZMJ-UHFFFAOYSA-N 0.000 description 3
- JUDXBRVLWDGRBC-UHFFFAOYSA-N [2-(hydroxymethyl)-3-(2-methylprop-2-enoyloxy)-2-(2-methylprop-2-enoyloxymethyl)propyl] 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(CO)(COC(=O)C(C)=C)COC(=O)C(C)=C JUDXBRVLWDGRBC-UHFFFAOYSA-N 0.000 description 3
- HVVWZTWDBSEWIH-UHFFFAOYSA-N [2-(hydroxymethyl)-3-prop-2-enoyloxy-2-(prop-2-enoyloxymethyl)propyl] prop-2-enoate Chemical compound C=CC(=O)OCC(CO)(COC(=O)C=C)COC(=O)C=C HVVWZTWDBSEWIH-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000007385 chemical modification Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 229940099472 immunoglobulin a Drugs 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 229940096397 interleukin-8 Drugs 0.000 description 3
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 3
- 229910052753 mercury Inorganic materials 0.000 description 3
- 230000008383 multiple organ dysfunction Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 229940096522 trimethylolpropane triacrylate Drugs 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- CFXQEHVMCRXUSD-UHFFFAOYSA-N 1,2,3-Trichloropropane Chemical compound ClCC(Cl)CCl CFXQEHVMCRXUSD-UHFFFAOYSA-N 0.000 description 2
- MHHJQVRGRPHIMR-UHFFFAOYSA-N 1-phenylprop-2-en-1-ol Chemical compound C=CC(O)C1=CC=CC=C1 MHHJQVRGRPHIMR-UHFFFAOYSA-N 0.000 description 2
- IGGDKDTUCAWDAN-UHFFFAOYSA-N 1-vinylnaphthalene Chemical compound C1=CC=C2C(C=C)=CC=CC2=C1 IGGDKDTUCAWDAN-UHFFFAOYSA-N 0.000 description 2
- QHVBLSNVXDSMEB-UHFFFAOYSA-N 2-(diethylamino)ethyl prop-2-enoate Chemical compound CCN(CC)CCOC(=O)C=C QHVBLSNVXDSMEB-UHFFFAOYSA-N 0.000 description 2
- DPBJAVGHACCNRL-UHFFFAOYSA-N 2-(dimethylamino)ethyl prop-2-enoate Chemical compound CN(C)CCOC(=O)C=C DPBJAVGHACCNRL-UHFFFAOYSA-N 0.000 description 2
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 2
- OBETXYAYXDNJHR-UHFFFAOYSA-N 2-Ethylhexanoic acid Chemical compound CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 108010052500 Calgranulin A Proteins 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- 102100031000 Hepatoma-derived growth factor Human genes 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010039020 Rhabdomyolysis Diseases 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 208000003441 Transfusion reaction Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- GCNKJQRMNYNDBI-UHFFFAOYSA-N [2-(hydroxymethyl)-2-(2-methylprop-2-enoyloxymethyl)butyl] 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(CO)(CC)COC(=O)C(C)=C GCNKJQRMNYNDBI-UHFFFAOYSA-N 0.000 description 2
- TUOBEAZXHLTYLF-UHFFFAOYSA-N [2-(hydroxymethyl)-2-(prop-2-enoyloxymethyl)butyl] prop-2-enoate Chemical compound C=CC(=O)OCC(CO)(CC)COC(=O)C=C TUOBEAZXHLTYLF-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000008081 blood perfusion Effects 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229920001002 functional polymer Polymers 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 102000017941 granulin Human genes 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 108010052188 hepatoma-derived growth factor Proteins 0.000 description 2
- ZNAOFAIBVOMLPV-UHFFFAOYSA-N hexadecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(C)=C ZNAOFAIBVOMLPV-UHFFFAOYSA-N 0.000 description 2
- PZDUWXKXFAIFOR-UHFFFAOYSA-N hexadecyl prop-2-enoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C=C PZDUWXKXFAIFOR-UHFFFAOYSA-N 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- MLFHJEHSLIIPHL-UHFFFAOYSA-N isoamyl acetate Chemical compound CC(C)CCOC(C)=O MLFHJEHSLIIPHL-UHFFFAOYSA-N 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- LKIPOGBWSIFYFM-UHFFFAOYSA-N n,n-bis(ethenyl)formamide Chemical compound C=CN(C=C)C=O LKIPOGBWSIFYFM-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- ZQXSMRAEXCEDJD-UHFFFAOYSA-N n-ethenylformamide Chemical compound C=CNC=O ZQXSMRAEXCEDJD-UHFFFAOYSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- NZIDBRBFGPQCRY-UHFFFAOYSA-N octyl 2-methylprop-2-enoate Chemical compound CCCCCCCCOC(=O)C(C)=C NZIDBRBFGPQCRY-UHFFFAOYSA-N 0.000 description 2
- 229940065472 octyl acrylate Drugs 0.000 description 2
- ANISOHQJBAQUQP-UHFFFAOYSA-N octyl prop-2-enoate Chemical compound CCCCCCCCOC(=O)C=C ANISOHQJBAQUQP-UHFFFAOYSA-N 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- HJWLCRVIBGQPNF-UHFFFAOYSA-N prop-2-enylbenzene Chemical compound C=CCC1=CC=CC=C1 HJWLCRVIBGQPNF-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 159000000000 sodium salts Chemical group 0.000 description 2
- BWYYYTVSBPRQCN-UHFFFAOYSA-M sodium;ethenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C=C BWYYYTVSBPRQCN-UHFFFAOYSA-M 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical class C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
- HGOUNPXIJSDIKV-UHFFFAOYSA-N 2,2-bis(hydroxymethyl)butyl 2-methylprop-2-enoate Chemical compound CCC(CO)(CO)COC(=O)C(C)=C HGOUNPXIJSDIKV-UHFFFAOYSA-N 0.000 description 1
- STMDPCBYJCIZOD-UHFFFAOYSA-N 2-(2,4-dinitroanilino)-4-methylpentanoic acid Chemical compound CC(C)CC(C(O)=O)NC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O STMDPCBYJCIZOD-UHFFFAOYSA-N 0.000 description 1
- MUUOUUYKIVSIAR-UHFFFAOYSA-N 2-but-3-enyloxirane Chemical compound C=CCCC1CO1 MUUOUUYKIVSIAR-UHFFFAOYSA-N 0.000 description 1
- SLJFKNONPLNAPF-UHFFFAOYSA-N 3-Vinyl-7-oxabicyclo[4.1.0]heptane Chemical compound C1C(C=C)CCC2OC21 SLJFKNONPLNAPF-UHFFFAOYSA-N 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- MAGFQRLKWCCTQJ-UHFFFAOYSA-N 4-ethenylbenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(C=C)C=C1 MAGFQRLKWCCTQJ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 206010066173 Allergic transfusion reaction Diseases 0.000 description 1
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 102000018803 Calgranulin A Human genes 0.000 description 1
- 108010052495 Calgranulin B Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical class COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 239000004803 Di-2ethylhexylphthalate Substances 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- GXBYFVGCMPJVJX-UHFFFAOYSA-N Epoxybutene Chemical compound C=CC1CO1 GXBYFVGCMPJVJX-UHFFFAOYSA-N 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 108700010013 HMGB1 Proteins 0.000 description 1
- 101150021904 HMGB1 gene Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000014702 Haptoglobin Human genes 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 102100037907 High mobility group protein B1 Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 102000005482 Lipopolysaccharide Receptors Human genes 0.000 description 1
- 108010031801 Lipopolysaccharide Receptors Proteins 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108010048233 Procalcitonin Proteins 0.000 description 1
- 102100032442 Protein S100-A8 Human genes 0.000 description 1
- 102100032420 Protein S100-A9 Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102000013674 S-100 Human genes 0.000 description 1
- 108700021018 S100 Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000012265 beta-defensin Human genes 0.000 description 1
- 108050002883 beta-defensin Proteins 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- ITMIAZBRRZANGB-UHFFFAOYSA-N but-3-ene-1,2-diol Chemical compound OCC(O)C=C ITMIAZBRRZANGB-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229960002380 dibutyl phthalate Drugs 0.000 description 1
- NKDDWNXOKDWJAK-UHFFFAOYSA-N dimethoxymethane Chemical class COCOC NKDDWNXOKDWJAK-UHFFFAOYSA-N 0.000 description 1
- BKJSEABPEJIDQT-UHFFFAOYSA-N dimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]-(3-sulfopropyl)azanium;hydroxide Chemical compound [OH-].CC(=C)C(=O)OCC[N+](C)(C)CCCS(O)(=O)=O BKJSEABPEJIDQT-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 1
- 238000010559 graft polymerization reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000013315 hypercross-linked polymer Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000008975 immunomodulatory function Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229940117955 isoamyl acetate Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000005501 phase interface Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 101150100677 polo gene Proteins 0.000 description 1
- 229920000779 poly(divinylbenzene) Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 239000007870 radical polymerization initiator Substances 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 229920013730 reactive polymer Polymers 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008020 response regulators Proteins 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- QGRSLAYMCFPMHW-UHFFFAOYSA-M sodium;3-(2-methylprop-2-enoyloxy)propane-1-sulfonate Chemical compound [Na+].CC(=C)C(=O)OCCCS([O-])(=O)=O QGRSLAYMCFPMHW-UHFFFAOYSA-M 0.000 description 1
- XFTALRAZSCGSKN-UHFFFAOYSA-M sodium;4-ethenylbenzenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C1=CC=C(C=C)C=C1 XFTALRAZSCGSKN-UHFFFAOYSA-M 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000000547 structure data Methods 0.000 description 1
- HIFJUMGIHIZEPX-UHFFFAOYSA-N sulfuric acid;sulfur trioxide Chemical compound O=S(=O)=O.OS(O)(=O)=O HIFJUMGIHIZEPX-UHFFFAOYSA-N 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/795—Polymers containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/165—Filtering accessories, e.g. blood filters, filters for infusion liquids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/264—Synthetic macromolecular compounds derived from different types of monomers, e.g. linear or branched copolymers, block copolymers, graft copolymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/265—Synthetic macromolecular compounds modified or post-treated polymers
- B01J20/267—Cross-linked polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
- B01J20/28069—Pore volume, e.g. total pore volume, mesopore volume, micropore volume
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/16—Organic material
- B01J39/18—Macromolecular compounds
- B01J39/20—Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- External Artificial Organs (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Description
[0001] 本明細書に開示される内容は、国立心肺血液研究所(NHLBI)によって授与された、契約番号:HHSN268201600006Cの下での政府支援でなされた。本明細書に開示される内容はまた、国防総省−中小企業技術革新研究プログラム(DOD−SBIR)によって授与された、契約番号:W81XWH−12−C−0038の下での政府支援でなされた。米国政府は、本明細書に開示される内容に一定の権利を有する。
[0002] 本出願は、米国仮特許出願番号:62/245,071(2015年10月22日出願)に対する優先権を主張する。該出願の内容は、参照により本明細書に組み込まれる。
[0003] 開示される発明は、多孔性ポリマー吸着剤の技術分野にある。開示される発明はまた、輸血反応を引き起こす可能性がある、血液及び血液製品中の汚染物質(限定されないが、カリウム、遊離ヘモグロビン、サイトカイン、生物活性脂質、及び免疫グロブリンが含まれる)を広範に低下させることの技術分野にある。追加的に、開示される発明は、限定されないが、カリウム、遊離ヘモグロビン、遊離ミオグロビン、サイトカイン、生物活性脂質、及び免疫グロブリンが含まれる汚染物質を組織破壊後の灌流又は血液灌流によって広範に除去することの技術分野にある。
[0019] 他の側面には、本明細書に記載の生体適合性ポリマー系を含んでなるデバイスに、又は好適な体外回路を経由して該デバイスに生理液を単回通過させる工程を含んでなる、灌流の方法が含まれる。
[0032] 「生体適合性」という用語は、生理液、生組織、又は生物体と吸着剤が接触状態にある時間の間に許容されない臨床変化を生じること無く、該生理液、生組織、又は生物体と該吸着剤が接触することが可能であることを意味すると定義される。
[0034] 本明細書に使用されるように、「生理液」という用語は、身体を起源とする液体であって、限定されないが、鼻咽頭、口腔、食道、胃、膵臓、肝臓、胸膜、心膜、腹膜、腸、前立腺、***、膣の分泌液、並びに、涙液、唾液、肺又は気管支分泌液、粘液、胆汁、血液、リンパ液、血漿、血清、滑液、脳脊髄液、尿、及び、熱傷又は創傷より滲出する液体のような、間質液、細胞内液、及び細胞外液を含めることができる。
[0037] 本発明の目的では、、「収着(sorb)」という用語は、「吸収と吸着によって吸収して結合すること」と定義される。
[0040] 「分散剤(dispersant)」又は「分散剤(dispersing agent)」という用語は、流動媒体に懸濁した非混和液滴の細分された配列に対して安定化効果を付与する物質として定義される。
[0042] 「マクロ網状合成」という用語は、(成長中のポリマー分子を相平衡によって決定される一定の分子サイズでモノマー液の外に追い出す)不活性沈殿剤の存在下でのモノマーのポリマーへの重合と定義され、これにより球状又はほとんど球状の対称性の固体でナノサイズのミクロゲル粒子が得られ、それが密に詰まって、オープンセル構造の有形細孔があるビーズとなる[米国特許第4,297,220号、Meitzner and Oline(1981年10月27日);R. L. Albright, Reactive Polymers, 4, 155-174 (1986)]。
[0049] 多孔性ポリ(スチレン−co−ジビニルベンゼン)樹脂上のコーティング/分散剤は、改善された生体適合性を該素材に浸透させる。
[0058] いくつかの方法において、望まれない分子は、サイトカイン、スーパー抗原、モノカイン、ケモカイン、インターフェロン、プロテアーゼ、酵素、ブラジキニンが含まれるペプチド、可溶性CD40リガンド、生物活性脂質、酸化脂質、無細胞ヘモグロビン、傷害関連分子パターン分子(DAMP)、病原体関連分子パターン分子(PAMP)、無細胞ミオグロビン、成長因子、糖タンパク質、プリオン、毒素、細菌毒素とウイルス毒素、内毒素、薬物、血管作用物質、異種抗原、抗体、及び正電荷イオン(限定されないが、カリウムが含まれる)から構成される、炎症性メディエーター及び刺激物質である。
[0078] 一般的な記載と以下の詳しい記載は、例示と説明のためでしかなくて、付帯の特許請求の範囲に明確化されるように、本発明を制限するものではない。本明細書に提供される本発明の詳しい記載に照らせば、当業者には、本発明の他の側面が明らかであろう。
[0084] 一般的な記載と以下の詳しい記載は、例示と説明のためでしかなくて、付帯の特許請求の範囲に明確化されるように、本発明を制限するものではない。本明細書に提供される本発明の詳しい記載に照らせば、当業者には、本発明の他の側面が明らかであろう。
[0086] 一般的な記載と以下の詳しい記載は、例示と説明のためでしかなくて、付帯の特許請求の範囲に明確化されるように、本発明を制限するものではない。本明細書に提供される本発明の詳しい記載に照らせば、当業者には、本発明の他の側面が明らかであろう。
[0090] 一般的な記載と以下の詳しい記載は、例示と説明のためでしかなくて、付帯の特許請求の範囲に明確化されるように、本発明を制限するものではない。本明細書に提供される本発明の詳しい記載に照らせば、当業者には、本発明の他の側面が明らかであろう。
[0095] 一般的な記載と以下の詳しい記載は、例示と説明のためでしかなくて、付帯の特許請求の範囲に明確化されるように、本発明を制限するものではない。本明細書に提供される本発明の詳しい記載に照らせば、当業者には、本発明の他の側面が明らかであろう。
[0099] 一般的な記載と以下の詳しい記載は、例示と説明のためでしかなくて、付帯の特許請求の範囲に明確化されるように、本発明を制限するものではない。本明細書に提供される本発明の詳しい記載に照らせば、当業者には、本発明の他の側面が明らかであろう。
[0101] 一般的な記載と以下の詳しい記載は、例示と説明のためでしかなくて、付帯の特許請求の範囲に明確化されるように、本発明を制限するものではない。本明細書に提供される本発明の詳しい記載に照らせば、当業者には、本発明の他の側面が明らかであろう。
[0103] 一般的な記載と以下の詳しい記載は、例示と説明のためでしかなくて、付帯の特許請求の範囲に明確化されるように、本発明を制限するものではない。本明細書に提供される本発明の詳しい記載に照らせば、当業者には、本発明の他の側面が明らかであろう。
(i)複数の細孔と(ii)スルホン酸塩官能基を含む、少なくとも1つのポリマーを含む生体適合性ポリマー系であって;
(i)広範囲のタンパク質ベースの毒素と炎症性メディエーター、及び(ii)正電荷イオンを吸着することが可能な前記ポリマー系。
態様2
前記毒素及び炎症性メディエーターが約0.5kDa未満〜約1,000kDaの分子量を有する、態様1の生体適合性ポリマー系。
態様3
前記毒素及び炎症性メディエーターが約1kDa未満〜約1,000kDaの分子量を有する、態様1の生体適合性ポリマー系。
態様4
該ポリマーの細孔構造が10Å〜40,000Åの範囲にある孔径の全容積を1gの乾燥ポリマーにつき0.1ccより多くて5.0cc未満に有する、態様1の生体適合性ポリマー系。
態様5
ポリマーが血液適合性である、態様1の生体適合性ポリマー系。
態様6
生体適合性を導入する(imbue)ために使用する薬剤が(i)ヘパリン又は(ii)ヘパリン模倣性ポリマーのいずれかである、態様1の生体適合性ポリマー系。
態様7
ポリマーが生成されてその後生体適合性であるように作製される、態様1の生体適合性ポリマー系。
態様8
生体適合性を導入するために使用する薬剤が(i)ヘパリン又は(ii)ヘパリン模倣性ポリマーのいずれかである、態様7の生体適合性導入修飾系。
態様9
ビーズ、ファイバー、モノリス型カラム、フィルム、膜、又は半透膜が限定されずに含まれ得る、固体支持体の形態を有する、態様1の生体適合性ポリマー系。
態様10
毒素と炎症性メディエーターが、サイトカイン、スーパー抗原、モノカイン、ケモカイン、インターフェロン、プロテアーゼ、酵素、ブラジキニンが含まれるペプチド、可溶性CD40リガンド、生物活性脂質、酸化脂質、無細胞ヘモグロビン、無細胞ミオグロビン、DAMPS、成長因子、糖タンパク質、プリオン、毒素、細菌毒素とウイルス毒素、PAMPS、内毒素、薬物、血管作用物質、異種抗原、抗体、及び正電荷イオンの1以上を含む、態様1の生体適合性ポリマー系。
態様11
正電荷イオンがカリウムである、態様1の生体適合性ポリマー系。
態様12
懸濁重合、乳化重合、塊状重合、又は沈殿重合を使用して前記ポリマーが作製される、態様1の生体適合性ポリマー系。
態様13
前記ポリマーが超架橋ポリマーである、態様1の生体適合性ポリマー系。
態様14
固体支持体が生体適合性ヒドロゲルコーティングを有する、態様9の生体適合性ポリマー系。
態様15
ポリマーが、すべての未反応の二重結合及びクロロメチル基の残余官能基を保持する温和条件下でスルホン化された超架橋性又はマクロ網状多孔性ポリマーの形態である、態様1の生体適合性ポリマー系。
態様16
未反応の二重結合又はクロロメチル基は、生体適合性及び血液適合性モノマー、架橋剤、又は低分子量オリゴマーの1以上を付着させるためにフリーラジカル又はS N 2型化学を介して修飾することができる、態様15の生体適合性ポリマー系。
態様17
多孔性ポリマーが、スルホン酸基又はその塩、塩化スルホニル、又はスルホン酸エステル基を含む、態様1の生体適合性ポリマー系。
態様18
スルホン酸基又はその塩、塩化スルホニル、又はスルホン酸エステル基を含むポリマーは、(i)未反応の二重結合を含有する作り置き多孔性ポリマーの(ii)スルホン酸基又はその塩を含有する重合性ビニルモノマーとのグラフト共重合によって生成されて、血液適合性ビニルモノマーを含む混合物を形成する、態様17の生体適合性ポリマー系。
態様19
架橋剤、血液適合性モノマー、モノマー、及び好適なポロゲンの存在下で共重合して、スルホン酸塩官能基を含有する多孔性ポリマー性のポリマーを生じる、スルホン酸基又はその塩を含有する重合性ビニルモノマーより構築される、態様1の生体適合性ポリマー系。
態様20
(i)約0.5kDa〜約1,000kDaの分子量を有する広範囲のタンパク質ベースの毒素、及び(ii)正電荷イオンを吸着することが可能である、態様1の生体適合性ポリマー系。
態様21
(i)約1kDa〜約1,000kDaの分子量を有する広範囲のタンパク質ベースの毒素、及び(ii)正電荷イオンを吸着することが可能である、態様1の生体適合性ポリマー系。
態様22
態様1〜態様21のいずれか1項の生体適合性ポリマー系を含むデバイスに、又は好適な体外回路を経由して該デバイスに生理液を単回通過させる工程を含む、灌流の方法。
態様23
態様1〜態様21のいずれか1項の生体適合性ポリマー系を含む、(i)広範囲のタンパク質ベースの毒素と炎症性メディエーター、及び(ii)正電荷イオンを生理液より除去するためのデバイス。
態様24
前記毒素及び炎症性メディエーターが約0.5kDa未満〜約1,000kDaの分子量を有する、態様23のデバイス。
態様25
前記毒素及び炎症性メディエーターが約1kDa未満〜約1,000kDaの分子量を有する、態様23のデバイス。
態様26
ポリマーが、該ポリマーを保持するのに適した、全血、濃厚赤血球、血小板、アルブミン、血漿、又はこれらのあらゆる組合せの輸血用の容器に収容される、態様1の生体適合性ポリマー系。
態様27
ポリマーが、該ポリマーを保持して体外回路へ組み込まれるのに適したデバイス中にある、態様1の生体適合性ポリマー系。
[0107] 一般的な記載と以下の詳しい記載は、例示と説明のためでしかなくて、付帯の特許請求の範囲に明確化されるように、本発明を制限するものではない。本明細書に提供される本発明の詳しい記載に照らせば、当業者には、本発明の他の側面が明らかであろう。
Claims (26)
- (i)複数の細孔と(ii)スルホン酸塩官能基を含む、少なくとも1つのポリマーを含む生体適合性ポリマー系であって;
(i)広範囲のタンパク質ベースの毒素と炎症性メディエーター、及び(ii)正電荷イオンを吸着することが可能な前記ポリマー系であって、
前記ポリマーが、すべての未反応の二重結合及びクロロメチル基の残余官能基を保持する温和条件下でスルホン化された超架橋性又はマクロ網状多孔性ポリマーの形態である、前記ポリマー系。 - 前記毒素及び炎症性メディエーターが約0.5kDa〜約1,000kDaの分子量を有する、請求項1の生体適合性ポリマー系。
- 前記毒素及び炎症性メディエーターが約1kDa〜約1,000kDaの分子量を有する、請求項1の生体適合性ポリマー系。
- 該ポリマーの細孔構造が10Å〜40,000Åの範囲にある孔径の全容積を1gの乾燥ポリマーにつき0.1ccより多くて5.0cc未満に有する、請求項1の生体適合性ポリマー系。
- ポリマーが血液適合性である、請求項1の生体適合性ポリマー系。
- 生体適合性を導入する(imbue)ために使用する薬剤が(i)ヘパリン又は(ii)ヘパリン模倣性ポリマーのいずれかである、請求項1の生体適合性ポリマー系。
- ポリマーが生成されてその後生体適合性であるように作製される、請求項1の生体適合性ポリマー系。
- 生体適合性を導入するために使用する薬剤が(i)ヘパリン又は(ii)ヘパリン模倣性ポリマーのいずれかである、請求項7の生体適合性導入修飾系。
- ビーズ、ファイバー、モノリス型カラム、フィルム、膜、又は半透膜が限定されずに含まれ得る、固体支持体の形態を有する、請求項1の生体適合性ポリマー系。
- 毒素と炎症性メディエーターが、サイトカイン、スーパー抗原、モノカイン、ケモカイン、インターフェロン、プロテアーゼ、酵素、ブラジキニンが含まれるペプチド、可溶性CD40リガンド、生物活性脂質、酸化脂質、無細胞ヘモグロビン、無細胞ミオグロビン、DAMPS、成長因子、糖タンパク質、プリオン、毒素、細菌毒素とウイルス毒素、PAMPS、内毒素、薬物、血管作用物質、異種抗原、抗体、及び正電荷イオンの1以上を含む、請求項1の生体適合性ポリマー系。
- 正電荷イオンがカリウムである、請求項1の生体適合性ポリマー系。
- 懸濁重合、乳化重合、塊状重合、又は沈殿重合を使用して前記ポリマーが作製される、請求項1の生体適合性ポリマー系。
- 前記ポリマーが超架橋ポリマーである、請求項1の生体適合性ポリマー系。
- 固体支持体が生体適合性ヒドロゲルコーティングを有する、請求項9の生体適合性ポリマー系。
- 未反応の二重結合又はクロロメチル基は、生体適合性及び血液適合性モノマー、架橋剤、又は低分子量オリゴマーの1以上を付着させるためにフリーラジカル又はSN2型化学を介して修飾することができる、請求項1の生体適合性ポリマー系。
- 多孔性ポリマーが、スルホン酸基又はその塩、塩化スルホニル、又はスルホン酸エステル基を含む、請求項1の生体適合性ポリマー系。
- スルホン酸基又はその塩、塩化スルホニル、又はスルホン酸エステル基を含むポリマーは、(i)未反応の二重結合を含有する作り置き多孔性ポリマーの(ii)スルホン酸基又はその塩を含有する重合性ビニルモノマーとのグラフト共重合によって生成されて、血液適合性ビニルモノマーを含む混合物を形成する、請求項16の生体適合性ポリマー系。
- 架橋剤、血液適合性モノマー、モノマー、及び好適なポロゲンの存在下で共重合して、スルホン酸塩官能基を含有する多孔性ポリマー性のポリマーを生じる、スルホン酸基又はその塩を含有する重合性ビニルモノマーより構築される、請求項1の生体適合性ポリマー系。
- (i)約0.5kDa〜約1,000kDaの分子量を有する広範囲のタンパク質ベースの毒素、及び(ii)正電荷イオンを吸着することが可能である、請求項1の生体適合性ポリマー系。
- (i)約1kDa〜約1,000kDaの分子量を有する広範囲のタンパク質ベースの毒素、及び(ii)正電荷イオンを吸着することが可能である、請求項1の生体適合性ポリマー系。
- 請求項1〜請求項20のいずれか1項の生体適合性ポリマー系を含む灌流デバイスであって、前記灌流が、前記デバイスに、又は好適な体外回路を経由して該デバイスに生理液を単回通過させることによってなされる、灌流デバイス。
- 請求項1〜請求項20のいずれか1項の生体適合性ポリマー系を含む、(i)広範囲のタンパク質ベースの毒素と炎症性メディエーター、及び(ii)正電荷イオンを生理液より除去するためのデバイス。
- 前記毒素及び炎症性メディエーターが約0.5kDa〜約1,000kDaの分子量を有する、請求項22のデバイス。
- 前記毒素及び炎症性メディエーターが約1kDa〜約1,000kDaの分子量を有する、請求項22のデバイス。
- ポリマーが、該ポリマーを保持するのに適した、全血、濃厚赤血球、血小板、アルブミン、血漿、又はこれらのあらゆる組合せの輸血用の容器に収容される、請求項1の生体適合性ポリマー系。
- ポリマーが、該ポリマーを保持して体外回路へ組み込まれるのに適したデバイス中にある、請求項1の生体適合性ポリマー系。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562245071P | 2015-10-22 | 2015-10-22 | |
US62/245,071 | 2015-10-22 | ||
PCT/US2016/058019 WO2017070415A1 (en) | 2015-10-22 | 2016-10-21 | Multi-functional hemocompatible porous polymer bead sorbent for removing protein based toxins an potassium from biological fluids |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019500917A JP2019500917A (ja) | 2019-01-17 |
JP6884774B2 true JP6884774B2 (ja) | 2021-06-09 |
Family
ID=58557781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018520396A Active JP6884774B2 (ja) | 2015-10-22 | 2016-10-21 | 生体液よりタンパク質ベースの毒素とカリウムを除去するための多機能性の血液適合性多孔性ポリマービーズ吸着剤 |
Country Status (8)
Country | Link |
---|---|
US (3) | US11040061B2 (ja) |
EP (1) | EP3365045A4 (ja) |
JP (1) | JP6884774B2 (ja) |
CN (1) | CN108136112B (ja) |
AU (1) | AU2016342263B2 (ja) |
CA (1) | CA3001698A1 (ja) |
RU (1) | RU2742768C2 (ja) |
WO (1) | WO2017070415A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
WO2012108920A1 (en) | 2011-02-09 | 2012-08-16 | Natera, Inc | Methods for non-invasive prenatal ploidy calling |
WO2016183106A1 (en) | 2015-05-11 | 2016-11-17 | Natera, Inc. | Methods and compositions for determining ploidy |
RU2742768C2 (ru) * | 2015-10-22 | 2021-02-10 | Сайтосорбентс Корпорейшн | Применение многофункционального гемосовместимого пористого полимерно гранулированного сорбента для удаления гемоглобина, калия, цитокинов, биоактивных липидов и иммуноглобулинов из биологических жидкостей |
US11065600B2 (en) * | 2016-05-26 | 2021-07-20 | Cytosorbents Corporation | Use of a hemocompatible porous polymer bead sorbent for removal of endotoxemia-inducing molecules |
EP3630325A4 (en) * | 2017-05-23 | 2021-02-17 | Cytosorbents Corporation | METHODS FOR TREATMENT OF TRAUMATIC BRAIN INJURY |
WO2018237075A1 (en) | 2017-06-20 | 2018-12-27 | The Medical College Of Wisconsin, Inc. | ASSESSING THE RISK OF GRAFT COMPLICATION WITH TOTAL ACELLULAR DNA |
JP2021520816A (ja) | 2018-04-14 | 2021-08-26 | ナテラ, インコーポレイテッド | 循環腫瘍dnaの個別化された検出を用いる癌検出およびモニタリングの方法 |
JP7309470B2 (ja) | 2018-07-02 | 2023-07-18 | 旭化成メディカル株式会社 | 血液処理用ビーズ |
CN109942737B (zh) * | 2019-03-13 | 2020-12-08 | 南京大学 | 粒径均匀的两亲性聚合物微球材料、制备方法和应用 |
US11931674B2 (en) | 2019-04-04 | 2024-03-19 | Natera, Inc. | Materials and methods for processing blood samples |
RU2727691C1 (ru) * | 2019-09-09 | 2020-07-22 | Николай Николаевич Петухов | УСТРОЙСТВО СОРБЦИОННОЙ ОБРАБОТКИ БИОЛОГИЧЕСКОЙ ЖИДКОСТИ И СПОСОБ ЕГО ПРИМЕНЕНИЯ (варианты) |
EP4132359A4 (en) * | 2020-04-07 | 2024-04-17 | Cytosorbents Corporation | BLOOD AND TOXIN FILTRATION DEVICE AND ITS USE |
CN115768459A (zh) * | 2020-04-14 | 2023-03-07 | 西托索尔本茨公司 | 通过免疫调节治疗改善免疫应答和减少免疫麻痹 |
WO2021236956A1 (en) * | 2020-05-20 | 2021-11-25 | The Medical College Of Wisconsin, Inc. | Compositions and methods for reducing cell-free dna |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL241315A (ja) | 1958-07-18 | |||
US4837015A (en) * | 1987-03-05 | 1989-06-06 | Carolina Medical Products Company, Inc. | Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels |
ES2049327T3 (es) | 1988-09-06 | 1994-04-16 | Rohm & Haas | Resinas de cambio de ion. |
ATE123658T1 (de) * | 1990-06-15 | 1995-06-15 | Cortrak Medical Inc | Vorrichtung zur abgabe von medikamenten. |
FR2721217B1 (fr) * | 1994-06-20 | 1996-08-02 | Hospal Ind | Dispositif multifonction pour le traitement du sang. |
JP3633978B2 (ja) * | 1994-12-26 | 2005-03-30 | 株式会社カネカ | 腫瘍壊死因子−αの吸着剤、吸着除去方法および吸着器 |
EP0800862B1 (en) * | 1994-12-26 | 2002-02-27 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Adsorbent for endotoxin, tumor necrosis factor-alpha or interleukins, method for removal via adsorption, and adsorber |
DE19549420A1 (de) * | 1995-04-27 | 1997-09-18 | Braun Melsungen Ag | Verfahren zur simultanen extrakorporalen Elimination von Tumor-Nekrose Faktor alpha (TNF alpha) und bakteriellen Lipopolysacchariden (LPS) aus Vollblut oder/und Blutplasma |
EP1179732B2 (en) * | 2000-08-11 | 2012-02-29 | Rohm And Haas Company | Polymeric adsorbent and method of preparation |
US6833153B1 (en) * | 2000-10-31 | 2004-12-21 | Advanced Cardiovascular Systems, Inc. | Hemocompatible coatings on hydrophobic porous polymers |
CN1228099C (zh) * | 2001-04-12 | 2005-11-23 | 可乐丽股份有限公司 | 体液处理用吸附器 |
JP5463506B2 (ja) * | 2005-03-16 | 2014-04-09 | 国立大学法人山口大学 | グラフトポリマー、高分子電解質膜、これらの製造方法、及びそれを用いた燃料電池 |
TWI326691B (en) | 2005-07-22 | 2010-07-01 | Kraton Polymers Res Bv | Sulfonated block copolymers, method for making same, and various uses for such block copolymers |
US20140046023A1 (en) * | 2009-07-28 | 2014-02-13 | Instraction Gmbh | Specific sorbent for binding proteins and peptides, and separation method using the same |
TWI590844B (zh) * | 2010-10-27 | 2017-07-11 | 東麗股份有限公司 | 血液成分吸附用載體及血液成分吸附管柱 |
US10064406B2 (en) * | 2011-01-06 | 2018-09-04 | Cytosorbents Corporation | Polymeric sorbent for removal of impurities from whole blood and blood products |
AU2012204277B2 (en) * | 2011-01-06 | 2015-11-05 | Cytosorbents Corporation | Compositions and methods useful in selectively modifying the internal and external surfaces of porous polymer beads |
US20120219633A1 (en) | 2011-02-28 | 2012-08-30 | Pall Corporation | Removal of immunoglobulins and leukocytes from biological fluids |
CN102838780B (zh) | 2011-06-23 | 2014-09-24 | 杜邦公司 | 改性纳米颗粒、其制备方法及其用于提高纤维基材之阳离子染色性的用途 |
US20150335576A1 (en) * | 2012-06-29 | 2015-11-26 | Cytosorbents Corporation | Methods of using polymers |
CN103497278B (zh) * | 2013-10-16 | 2016-01-20 | 苏州大学 | 一种两性纤维素材料及其应用 |
RU2742768C2 (ru) * | 2015-10-22 | 2021-02-10 | Сайтосорбентс Корпорейшн | Применение многофункционального гемосовместимого пористого полимерно гранулированного сорбента для удаления гемоглобина, калия, цитокинов, биоактивных липидов и иммуноглобулинов из биологических жидкостей |
-
2016
- 2016-10-21 RU RU2018114640A patent/RU2742768C2/ru active
- 2016-10-21 EP EP16858260.9A patent/EP3365045A4/en active Pending
- 2016-10-21 WO PCT/US2016/058019 patent/WO2017070415A1/en active Application Filing
- 2016-10-21 CN CN201680061722.5A patent/CN108136112B/zh active Active
- 2016-10-21 CA CA3001698A patent/CA3001698A1/en active Pending
- 2016-10-21 US US15/769,361 patent/US11040061B2/en active Active
- 2016-10-21 JP JP2018520396A patent/JP6884774B2/ja active Active
- 2016-10-21 AU AU2016342263A patent/AU2016342263B2/en active Active
-
2021
- 2021-06-08 US US17/341,912 patent/US11723916B2/en active Active
-
2023
- 2023-06-30 US US18/345,683 patent/US20240016830A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2018114640A3 (ja) | 2020-02-27 |
CA3001698A1 (en) | 2017-04-27 |
RU2018114640A (ru) | 2019-11-25 |
CN108136112B (zh) | 2021-07-30 |
AU2016342263B2 (en) | 2021-07-22 |
CN108136112A (zh) | 2018-06-08 |
EP3365045A1 (en) | 2018-08-29 |
US20180303870A1 (en) | 2018-10-25 |
AU2016342263A1 (en) | 2018-04-26 |
WO2017070415A1 (en) | 2017-04-27 |
US11040061B2 (en) | 2021-06-22 |
EP3365045A4 (en) | 2019-07-03 |
JP2019500917A (ja) | 2019-01-17 |
US20210401874A1 (en) | 2021-12-30 |
US11723916B2 (en) | 2023-08-15 |
US20240016830A1 (en) | 2024-01-18 |
RU2742768C2 (ru) | 2021-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6884774B2 (ja) | 生体液よりタンパク質ベースの毒素とカリウムを除去するための多機能性の血液適合性多孔性ポリマービーズ吸着剤 | |
CA2823953C (en) | Polymeric sorbent for removal of impurities from whole blood and blood products | |
US11020521B2 (en) | Hemocompatibility modifiers for cross-linked polymeric material | |
JP7305825B2 (ja) | 内毒素血症誘発分子を除去するための血液適合性多孔質ポリマービーズ収着材の使用 | |
JP6138783B2 (ja) | 全血および血液製剤から不純物を除去するためのポリマー収着剤 | |
JPH01119264A (ja) | 吸着体およびそれを用いた除去装置 | |
JPH0667472B2 (ja) | 血清アミロイドp蛋白用吸着体 | |
JPH0611333B2 (ja) | 免疫複合体の吸着体およびそれを用いた免疫複合体の除去装置 | |
JP2665526B2 (ja) | β2−ミクログロブリンの吸着材 | |
JPH0771632B2 (ja) | 吸着体およびそれを用いた除去装置 | |
BR112020003638A2 (pt) | redução de produtos finais de glicação avançada a partir de fluidos corporais |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191018 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200930 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201012 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210312 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210412 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210512 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6884774 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |